International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

By J. Vose, J. Armitage, D. Weisenburger. Journal of Clinical Oncology, 2008

1,904 citations recorded by the source corpus.

Subfields: Immunology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2003cf46b583041e39acbf3d9218554f446786db

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Crump
2. L. Popplewell
3. A. Goy
4. E. Hsi
5. M. Lechowicz
6. C. Gisselbrecht
7. R. Furman

Citations in the corpus

• Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. (2011, background): “© 2011 by American Society of Clinical Oncology INTRODUCTION Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of mature T- and natural killer (NK) -cell neoplasms, accounting for 10% to 15% of newly diagnosed cases of non-Hodgkin’s lymphoma (NHL) in North America.1-4 Based on the W”